In the twenty-first century, much of the advancement in the knowledge of gastrointestinal disorders has continued to focus on the molecular underpinnings of gastrointestinal cancer. Molecularly targeted drugs have had a significant influence on the treatment of a variety of cancers.
In the complete examination of patients with suspected or established intestinal disease, biochemical testing plays a vital role. They are the most common tests used to monitor changes in gastric and intestinal function, as well as the nutritional status of those who have stomach and intestine disorders. Protein loss, altered motility, and immunological reactions are among the various characteristics of gastrointestinal diseases for which biochemical testing is used.
Digestion and absorption of ingested food and liquids are controlled by the gastrointestinal (GI) system. Because of the GI tract's intricacy and the large amount of material that may be included under the purview of GI physiology. There is abundant evidence that psychological and physical stressors have a significant influence in the onset and management of GI disorders.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Complex endoscopy in pediatrics: Optimizing care
Monique Barakat, Stanford University School of Medicine, United States
Title : Use of indocyanine green fluorescence imaging in the extrahepatic biliary tract surgery
Orestis Ioannidis, Aristotle University of Thessaloniki, Greece
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States
Title : Efficacy of Sertraline on the symptoms and quality of life in patients with irritable bowel syndrome: A single-blinded and parallel designed randomized controlled trial
Sara Seifouri, St. Thomas NHS Foundation Trust, United Kingdom